{rfName}
Sa

Indexed in

License and Use

Icono OpenAccess

Citations

10

Altmetrics

Analysis of institutional authors

Tous, SAuthorCirauqui, BAuthor

Share

January 15, 2026
Publications
>
Article
Sí

Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma

Publicated to: Frontiers in Oncology. 14 1458479- - 2024-11-25 14(), DOI: 10.3389/fonc.2024.1458479

Authors:

Llop, S; Plana, M; Tous, S; Ferrando-Diez, A; Brenes, J; Juarez, M; Vidales, Z; Vilajosana, E; Linares, I; Arribas, L; Duch, M; Fulla, M; Brunet, A; Lozano, A; Cirauqui, B; Mesía, R; Oliva, M
[+]

Affiliations

Catalan Inst Oncol ICO, Dept Med Oncol, Lhospitalet De Llobregat - Author
Catalan Inst Oncol ICO, Dept Radiat Oncol, Lhospitalet De Llobregat - Author
CIBER Epidemiol & Salud Publ CIBERESP - Author
Hosp Univ Bellvitge, Dept Oral & Maxillofacial Surg - Author
Hosp Univ Bellvitge, Dept Otorhinolaryngol & Head & Neck Surg - Author
IGTP, Catalan Inst Oncol ICO, B ARGO Grp, Dept Med Oncol - Author
Univ Barcelona, Catalan Inst Oncol ICO, Clin Nutr Unit, IDIBELL, Lhospitalet De Llobregat - Author
See more

Abstract

Objectives Anti-PD-(L)1 agents changed the landscape of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treatment. Previous studies showed improved response rates to salvage chemotherapy (SCT) after progression to anti-PD-(L)1 agents. This study aims to evaluate the outcomes of SCT and to identify predictors of response and survival in patients with R/M HNSCC. Materials and methods Retrospective cohort analysis of 63 R/M patients treated with SCT after antiPD-(L1)-based therapy between January 2015 and August 2022. The overall response rate (ORR) was evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated with Kaplan-Meier method. Progression-free survival 2 was calculated from anti-PD-(L)1-therapy start until progression to SCT (PFS2-I). Logistic regression and Cox regression analyses were performed to identify predictors of outcome. Results A total of 63 patients were included: 76% were men, and median age was 60 years. PD-L1 status was available in 68% (61% positive). Up to 71% received SCT as third line or beyond. ORR to SCT was 49% with higher rates in PD-L1 positive tumors, 71% vs. 18% (p=0.001), and cetuximab-containing regimens, 68% vs. 39% (p=0.026). PD-L1 status was the only predictor of ORR in the adjusted model (OR=8.6, 95% CI 1.7-43.0). OS and PFS were 9.3 months (95% CI, 6.5-12.3) and 4.1 months (95% CI, 3.0-5.8) respectively. PFS2-I was 8.6 months (95% CI, 6.6-10.5). In the multivariate analysis, PD-L1 was the only independent factor for OS (HR=0.3; 95% CI, 0.1-0.7), PFS (HR=0.2; 95% CI, 0.1-0.5; p
[+]

Keywords

AdultAgedAnti-pd-(l)1ArticleCancerCancer chemotherapyCancer growthCancer immunotherapyCancer recurrenceCetuximabCohort analysisComputer assisted tomographyDisease controlDisease exacerbationEcog performance statusExpressionFemaleFollow upHead and neckHead and neck squamous cell carcinomaHnsccHumanImmune checkpoint inhibitorsImmunohistochemistryImmunotherapyKaplan meier methodMajor clinical studyMaleMouth cavityMulticenter studyMultivariate analysisNivolumabOpen-labelOropharynx cancerOutcome assessmentOverall response rateOverall survivalPaclitaxelPathological complete responsePembrolizumabPersonalized medicinePlus cetuximabPolymerase chain reactionPractice guidelineProgression free survivalRatesRecurrentRetrospective studySalvage chemotherapySalvage therapySctSquamous cell carcinomaTreatment responseTreatment sequencingTumor volume

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Frontiers in Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 123/328, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Oncology. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Oncology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-04:

  • WoS: 5
  • Scopus: 5
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 8.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 7 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

    It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

    • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
    [+]

    Leadership analysis of institutional authors

    There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Llop, S) and Last Author (Oliva, M).

    the author responsible for correspondence tasks has been Oliva, M.

    [+]